Here is the TLTFF info without the newsletter sign up which is being deleted....
They always are here on Coffee Shoppe.
Theralase Technologies Inc., ticker symbol TLTFF is a newly listed foreign issue with its main counter part trading on the TSX as TLT.V, a Canadian based exchange. TLTFF however can be traded on the open market in the United States under the ticker symbol TLTFF.
We did our due diligence and we feel that TLTFF is fairly undervalued at the current price per share of 0.34. We also spoke with the company who seems very eager and confident towards gaining FDA approval on several of their applications as pre-trials and trials continue to display positive results. We also anticipate that the company will soon get all of their filings together so that their newly listed U.S. counterpart “TLTFF,” can become fully reporting.
Just one of TLTFFs patented technologies, TLC-1000 which is a cold laser technology for non-invasive pain management currently generates ~$2 million of revenue annually through 1200 practitioners
Its also interesting to note that currently over 3,000 clinical studies worldwide have proven the success of therapeutic lasers in the healing of neural muscular-skeletal conditions. Theralase has performed a blinded randomized control study on chronic knee pain proving the clinical efficacy of Theralase therapeutic laser technology and achieving FDA 510(k) approval for chronic knee pain.
About Theralase
Theralase Technologies Inc. designs, manufactures and markets patented, FDA approved super-pulsed laser technology used in healing injured tissue and destroying cancer. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses. Theralase lasers are FDA, Health Canada and CSA/UL approved, and have international ISO 13485 certification.
Theralase’s strategy includes two parts: production, marketing and distribution of the Theralase super-pulsed laser for sale to health-care practitioners (focusing on the treatment of chronic pain, sports injuries and wounds); and commercialization of (i) patented cancer treatment through progressive research, clinical trials and advancement of new technology in the direct destruction of cancers and (ii) destruction of bacteria and viruses through research utilizing patented, light-sensitive Photo Dynamic Compounds
Value Driven Milestones & Upcoming Catalysts
Q1’ 12 – Successful preclinical studies showing complete destruction of various brain and colon cancer cell lines in-vivo and in live animal trials using Theralase PDCs
Q3’ 12 – Bladder Cancer identified as primary target for Advanced Photo Dynamic Therapy in FDA clinical trials
Q3’ 12 – Developed commercialization path for PDC technology to FDA Phase 1/2a clinical trials
Q4’ 13 – TLC-2000 Therapeutic biofeedback medical laser to be launched to healthcare practitioners
Q1’ 14 – Entering FDA phase 1 bladder cancer clinical trials
Q4’ 15 – Successfully completed 12 month follow-up of bladder cancer clinical trial.
Also anticipating the upcoming launch of TLC-2000 Biofeedback Therapeutic Laser employing a recurring revenue model. Commence TLC-3000 and PDC small animal in vivo pre-clinical trial for cancer destruction
What Makes its Interesting?
Large U.S. Market Opportunity…..
More than 56 million patients suffer from acute and chronic pain, in the U.S. with the market opportunity estimated at over $100 billion annually. The public’s desire for highly effective, drug-free treatments in an aging population is creating a significant opportunity for Theralase
Proprietary laser technology that effectively treats pain, inflammation and heals wounds without the side effects of drugs
Growth strategy to expand into the U.S. market, introduce a recurring revenue model.
R&D into combining PDCs with laser technology to destroy cancers, bacteria, and viruses.
Attractive ROI.
Proven Technology
Cold lasers are clinically proven to be the fastest and most effective method of treating pain.
Over 3,000 clinical studies worldwide support the clinical efficacy of cold lasers.
Cold lasers have no side effects, are non-invasive and provide drug-free treatment.
Theralase cold lasers have FDA, Health Canada and CE approval.
Other Key Notes and Interests
Proven clinical technology (TLC-1000)
Commercial therapeutic laser business and brand developed over last 17 years
No debt
Positive cash flow / double digit growth
PDC cancer destruction in animals helps pay for human trials
Competitive technical advantage (Cellular pathways: iNOS, ATP, Na+ / K+)
Large addressable US market ($ billions)
Future technology (Patented biofeedback technology and patented PDC cancer destruction)
Opportunity for growth (revenue, profit)
IP protection (multiple issued patents)
Experienced management team (20+ years)
Clear vision and execution strategy
Key Investment Highlights
Developing a therapeutic compound for the $3.9 billion bladder cancer market
Proven ability to develop and commercialize technologies: TLC-1000 cold laser technology for non-invasive pain management currently generates ~$2 million of revenue annually through 1200 practitioners
Platform technology for development of additional cancer therapeutics
Favorable preclinical data (vitro and in-vitro) in bladder and breast cancer cell lines
Partnership validation: Ontario Cancer Institute at Princess Margaret Hospital University Health Network
Second generation (TLC-2000) launch in 2014, along with a new recurring revenue business model
Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
Proprietary technology with strong IP portfolio: patented biofeedback technology and patented PDC cancer destruction, multiple issued patents
Large addressable US and World markets (several billions of dollars)
Strong financials: No debt, positive cash flow / double digit growth
Experienced leadership team (20+ years)
Anti-Cancer Platform Technology
Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Through studies conducted internally and independently Theralase’s PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. A recent mouse model demonstrated complete destruction of subcutaneous bladder cancer tumors. The study was an important milestone signifying that the company’s leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring.
Favorable preclinical data
Up to 100% cancer cell kill at very low concentrations (< 0.8μM)
More effective at killing cancer cells than already approved therapies: (668,000x ALA, 198x Photofrin)
Survival of mice up to 20 months (50 human years) after a single Theralase PDT treatment
Growth Strategy
TLC-2000 – Theralase will launch the new patented biofeedback laser system in Q4’ 13 using a recurring revenue model and will provide upgrade incentives to existing TLC-1000 customers.
TLC-3000 – Theralase will continue R&D in combining patented Photodynamic Compounds with the company’s patented laser technology to enter the cancer destruction market leading to a FDA phase 1/2a clinical trial in Q1’ 14.
Key Products
TLC-1000 Laser Treatment
Target Audience: Physicians, Physiotherapists, Chiropractors and Athletic Trainers
Endorsed by: Professional Sports teams including the Toronto Blue Jays, Montreal Canadians,
Washington Wizards and Toronto FC.
Key Benefits
TLC-1000 super-pulsed technology generates the highest peak power of all Class 3 cold lasers for the greatest depth of penetration.
Targets three cellular healing pathways; ATP for energizing cells, iNOS for elimination of inflammation and the lipid bilayer pathway for pain removal.
Offers more pre-programmed treatment protocols than competitive cold lasers.
Can be used unattended allowing practitioners to treat multiple patients simultaneously.
TLC-2000 Laser Treatment Patented
Theralase will commence selling its next generation therapeutic laser, the TLC-2000, in Q4 2013.
The patented TLC-2000 laser has the ability to more precisely treat pain and wounds by delivering exact energy doses to precise tissue locations and has a learning feature to record the most effective treatments.
Theralase has commissioned clinical studies by the University of Buffalo to demonstrate the efficacy of the new biofeedback technology.
Cumulative ROI: Year 1: 100% Year 3: 300%, Year 5: 500%
TLC-3000 Laser Treatment Patented
Theralase is researching and developing patented photodynamic compounds (PDCs) with patented laser technology to destroy cancers, bacteria, and viruses.
Success in initial results using PDCs to destroy cancer cells announced Q1’ 12.
Theralase PDC’s successful in destroying breast, colon, brain and bladder cancer cells.
Destruction of cancer tumors in a live animal model using Theralase light activated PDC’s Q1’ 12.
Cumulative ROI: Year 1: 0%, Year 3: 1100%, Year 5: 1200%
Recent News and Announcements
Feb 13, 2014 Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra…
Feb 12, 2014 Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market
Theralase Releases Financial Results for First Quarter 2013 2013-06-03
Theralase Launches New Head Office and Therapeutic Laser Centre 2013-05-28
Theralase Advanced Cancer Therapy Research Recognized at Major International Conference 2013-05-16
Theralase Announces 2012 Year End Financials 2013-05-02
Theralases Innovative Anti-Cancer Technology Validated at Major International Conferences 2013-04-25
Theralase Applies to TSX Venture Exchange for Warrant Extension 2013-04-01
Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 2013-03-20
Renowned Oncologist Dr. Michael Jewett Joins Theralase’s Medical and Scientific Advisory Board 2013-02-01
They always are here on Coffee Shoppe.
Theralase Technologies Inc., ticker symbol TLTFF is a newly listed foreign issue with its main counter part trading on the TSX as TLT.V, a Canadian based exchange. TLTFF however can be traded on the open market in the United States under the ticker symbol TLTFF.
We did our due diligence and we feel that TLTFF is fairly undervalued at the current price per share of 0.34. We also spoke with the company who seems very eager and confident towards gaining FDA approval on several of their applications as pre-trials and trials continue to display positive results. We also anticipate that the company will soon get all of their filings together so that their newly listed U.S. counterpart “TLTFF,” can become fully reporting.
Just one of TLTFFs patented technologies, TLC-1000 which is a cold laser technology for non-invasive pain management currently generates ~$2 million of revenue annually through 1200 practitioners
Its also interesting to note that currently over 3,000 clinical studies worldwide have proven the success of therapeutic lasers in the healing of neural muscular-skeletal conditions. Theralase has performed a blinded randomized control study on chronic knee pain proving the clinical efficacy of Theralase therapeutic laser technology and achieving FDA 510(k) approval for chronic knee pain.
About Theralase
Theralase Technologies Inc. designs, manufactures and markets patented, FDA approved super-pulsed laser technology used in healing injured tissue and destroying cancer. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses. Theralase lasers are FDA, Health Canada and CSA/UL approved, and have international ISO 13485 certification.
Theralase’s strategy includes two parts: production, marketing and distribution of the Theralase super-pulsed laser for sale to health-care practitioners (focusing on the treatment of chronic pain, sports injuries and wounds); and commercialization of (i) patented cancer treatment through progressive research, clinical trials and advancement of new technology in the direct destruction of cancers and (ii) destruction of bacteria and viruses through research utilizing patented, light-sensitive Photo Dynamic Compounds
Value Driven Milestones & Upcoming Catalysts
Q1’ 12 – Successful preclinical studies showing complete destruction of various brain and colon cancer cell lines in-vivo and in live animal trials using Theralase PDCs
Q3’ 12 – Bladder Cancer identified as primary target for Advanced Photo Dynamic Therapy in FDA clinical trials
Q3’ 12 – Developed commercialization path for PDC technology to FDA Phase 1/2a clinical trials
Q4’ 13 – TLC-2000 Therapeutic biofeedback medical laser to be launched to healthcare practitioners
Q1’ 14 – Entering FDA phase 1 bladder cancer clinical trials
Q4’ 15 – Successfully completed 12 month follow-up of bladder cancer clinical trial.
Also anticipating the upcoming launch of TLC-2000 Biofeedback Therapeutic Laser employing a recurring revenue model. Commence TLC-3000 and PDC small animal in vivo pre-clinical trial for cancer destruction
What Makes its Interesting?
Large U.S. Market Opportunity…..
More than 56 million patients suffer from acute and chronic pain, in the U.S. with the market opportunity estimated at over $100 billion annually. The public’s desire for highly effective, drug-free treatments in an aging population is creating a significant opportunity for Theralase
Proprietary laser technology that effectively treats pain, inflammation and heals wounds without the side effects of drugs
Growth strategy to expand into the U.S. market, introduce a recurring revenue model.
R&D into combining PDCs with laser technology to destroy cancers, bacteria, and viruses.
Attractive ROI.
Proven Technology
Cold lasers are clinically proven to be the fastest and most effective method of treating pain.
Over 3,000 clinical studies worldwide support the clinical efficacy of cold lasers.
Cold lasers have no side effects, are non-invasive and provide drug-free treatment.
Theralase cold lasers have FDA, Health Canada and CE approval.
Other Key Notes and Interests
Proven clinical technology (TLC-1000)
Commercial therapeutic laser business and brand developed over last 17 years
No debt
Positive cash flow / double digit growth
PDC cancer destruction in animals helps pay for human trials
Competitive technical advantage (Cellular pathways: iNOS, ATP, Na+ / K+)
Large addressable US market ($ billions)
Future technology (Patented biofeedback technology and patented PDC cancer destruction)
Opportunity for growth (revenue, profit)
IP protection (multiple issued patents)
Experienced management team (20+ years)
Clear vision and execution strategy
Key Investment Highlights
Developing a therapeutic compound for the $3.9 billion bladder cancer market
Proven ability to develop and commercialize technologies: TLC-1000 cold laser technology for non-invasive pain management currently generates ~$2 million of revenue annually through 1200 practitioners
Platform technology for development of additional cancer therapeutics
Favorable preclinical data (vitro and in-vitro) in bladder and breast cancer cell lines
Partnership validation: Ontario Cancer Institute at Princess Margaret Hospital University Health Network
Second generation (TLC-2000) launch in 2014, along with a new recurring revenue business model
Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
Proprietary technology with strong IP portfolio: patented biofeedback technology and patented PDC cancer destruction, multiple issued patents
Large addressable US and World markets (several billions of dollars)
Strong financials: No debt, positive cash flow / double digit growth
Experienced leadership team (20+ years)
Anti-Cancer Platform Technology
Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Through studies conducted internally and independently Theralase’s PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. A recent mouse model demonstrated complete destruction of subcutaneous bladder cancer tumors. The study was an important milestone signifying that the company’s leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring.
Favorable preclinical data
Up to 100% cancer cell kill at very low concentrations (< 0.8μM)
More effective at killing cancer cells than already approved therapies: (668,000x ALA, 198x Photofrin)
Survival of mice up to 20 months (50 human years) after a single Theralase PDT treatment
Growth Strategy
TLC-2000 – Theralase will launch the new patented biofeedback laser system in Q4’ 13 using a recurring revenue model and will provide upgrade incentives to existing TLC-1000 customers.
TLC-3000 – Theralase will continue R&D in combining patented Photodynamic Compounds with the company’s patented laser technology to enter the cancer destruction market leading to a FDA phase 1/2a clinical trial in Q1’ 14.
Key Products
TLC-1000 Laser Treatment
Target Audience: Physicians, Physiotherapists, Chiropractors and Athletic Trainers
Endorsed by: Professional Sports teams including the Toronto Blue Jays, Montreal Canadians,
Washington Wizards and Toronto FC.
Key Benefits
TLC-1000 super-pulsed technology generates the highest peak power of all Class 3 cold lasers for the greatest depth of penetration.
Targets three cellular healing pathways; ATP for energizing cells, iNOS for elimination of inflammation and the lipid bilayer pathway for pain removal.
Offers more pre-programmed treatment protocols than competitive cold lasers.
Can be used unattended allowing practitioners to treat multiple patients simultaneously.
TLC-2000 Laser Treatment Patented
Theralase will commence selling its next generation therapeutic laser, the TLC-2000, in Q4 2013.
The patented TLC-2000 laser has the ability to more precisely treat pain and wounds by delivering exact energy doses to precise tissue locations and has a learning feature to record the most effective treatments.
Theralase has commissioned clinical studies by the University of Buffalo to demonstrate the efficacy of the new biofeedback technology.
Cumulative ROI: Year 1: 100% Year 3: 300%, Year 5: 500%
TLC-3000 Laser Treatment Patented
Theralase is researching and developing patented photodynamic compounds (PDCs) with patented laser technology to destroy cancers, bacteria, and viruses.
Success in initial results using PDCs to destroy cancer cells announced Q1’ 12.
Theralase PDC’s successful in destroying breast, colon, brain and bladder cancer cells.
Destruction of cancer tumors in a live animal model using Theralase light activated PDC’s Q1’ 12.
Cumulative ROI: Year 1: 0%, Year 3: 1100%, Year 5: 1200%
Recent News and Announcements
Feb 13, 2014 Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra…
Feb 12, 2014 Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market
Theralase Releases Financial Results for First Quarter 2013 2013-06-03
Theralase Launches New Head Office and Therapeutic Laser Centre 2013-05-28
Theralase Advanced Cancer Therapy Research Recognized at Major International Conference 2013-05-16
Theralase Announces 2012 Year End Financials 2013-05-02
Theralases Innovative Anti-Cancer Technology Validated at Major International Conferences 2013-04-25
Theralase Applies to TSX Venture Exchange for Warrant Extension 2013-04-01
Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 2013-03-20
Renowned Oncologist Dr. Michael Jewett Joins Theralase’s Medical and Scientific Advisory Board 2013-02-01
